There are few efficient therapeutic approaches to hepatocarcinoma.Chen et al1 developed iodine (131I) metuximab injection (Licartin),a novel 131I-labeled HAb18G/CD147-specific monoclonal antibody Fab'2 fragment.H...There are few efficient therapeutic approaches to hepatocarcinoma.Chen et al1 developed iodine (131I) metuximab injection (Licartin),a novel 131I-labeled HAb18G/CD147-specific monoclonal antibody Fab'2 fragment.HAb18G/CD147 is a hepatocellular carcinoma-associated antigen.But their results have no obvious improvements in survival rate of patients with hepatocarcinoma.Keywords:radiation effects; promoter regions, genetic lentivirus; cytosine deaminase; fluorocytosine; HepG2 cells展开更多
基金This work was supported by grants from Beijing Natural Science Foundation (No.7083115 and 7112129),and Key Laboratory of Nuclear Medicine,Ministry of Health,Jiangsu Key Laboratory of Molecular Nuclear Medicine,Jiangsu Institute of Nuclear Medicine (No.KF201101).
文摘There are few efficient therapeutic approaches to hepatocarcinoma.Chen et al1 developed iodine (131I) metuximab injection (Licartin),a novel 131I-labeled HAb18G/CD147-specific monoclonal antibody Fab'2 fragment.HAb18G/CD147 is a hepatocellular carcinoma-associated antigen.But their results have no obvious improvements in survival rate of patients with hepatocarcinoma.Keywords:radiation effects; promoter regions, genetic lentivirus; cytosine deaminase; fluorocytosine; HepG2 cells